PelliScope

AI-Powered Dermatological Decision Support

01 | The Product

Clinically-Validated AI
For Any Workflow

Ready to Deploy For

Pre-Medical Inquiry

Triage before the patient sees a doctor
Tele-Medicine Consultation

Cost-effective remote patient consultation
In-Patient Appointment Schedule

Prioritize urgency while sharing interim home care guidance

Patient Scan: #8829-A

ANALYSIS COMPLETE

Primary Detection

Herpes Zoster

74%

Confidence

Allergic Dermatitis59%

80.2% Accuracy on Clinical Validation

Core Capabilities

Instant Clinical Support

Instantly distinguishes between infectious vs. non-infectious lesions to protect staff.

Diagnostic Assessment

Probability scoring for 10 common conditions (Eczema, Psoriasis, Tinea, etc.).

CPU-Optimized

Resource optimized for any hardware. On-premises deployable—data never leaves your control.

The Opportunity

Strategic Entry & Market Potential

02 | Strategic Roadmap

Upcoming Technology Showcase & GCC Opportunity

PelliScope has been shortlisted for a proof-of-concept demonstration by a major healthcare provider in the UAE. We will be co-presenting at an upcoming health conference, creating a critical entry point into the GCC market.

Arab Health 2026

Official technology showcase under our partner's booth. High visibility.

Co-Development

Foundation for a localized, robust dermatological AI model standard for the UAE.

Total Addressable Market

$1.9 Billion

2024 Global AI Dermatology Valuation

Projected $6–8B market by 2035

Current focus: GCC + US hospital systems

Growth Rate

33% CAGR

Projected growth 2025–2035

Demand driven by tele-derm adoption + onsite triage

Arab Health 2026 showcase anchors GCC entry

Revenue Model

$15k/mo

Per-user licensing + $0.50 SaaS inquiry fee

• Licensing: hospital deployments ($15k/user/month)
• SaaS: $0.50 per self-screening inquiry at scale
• White-label: private dermatology networks

Investment

Scaling PelliScope AI

03 | Funding Requirements

HawkFranklin Research is bootstrapped and ready to scale. We are launching a new Dubai-based entity to service GCC partnerships and are seeking capital for two distinct goals:

PHASE 1

Urgent Capital

$15,000

Execute PoC for Arab Health 2026
Cover initial Dubai setup & logistics

PHASE 2

Seed Scale

$1.5M

Full UAE product adaptation
Scale team & validate on new diseases

Projected ARR (18 Mo)

$2.1 Million

Early Investor Potential

5x ROI

Future Directions

• Extend differential AI to rare skin diseases, including melanoma
• Pair with longitudinal EHR data for chronic patient monitoring

Current Rollout Plan

• Clinical deployment in UAE by Aug 2026
• Expansion into India by Sep 2026
• GCC-wide rollout by March 2027

Get In Touch

Email Us

invest@hawkfranklin.in

HawkFranklin Research is a deep-tech company specializing in clinical AI solutions.

Leadership

The PelliScope Team

04 | PelliScope Team

Vatsal Patel

Founder & Research Engineer

M.Sc Artificial Intelligence (IU Berlin)

Dr. Abhijeet Patel

Clinical Research Physician

Bachelor of Medicine & Surgery

Dr. Yash Patel

Clinical Research Physician

Bachelor of Medicine & Surgery

Dr. Nishi Seth

Consultant Dermatologist

M.D Dermatology

Saurav Roy

Operations Head

M.Tech Biotechnology

Ananya Pal

Finance & Accounting Head

B.S Economics

Vision & Portfolio

How HawkFranklin Operates

Operational Revenue Model

Path A: HFR-Initiated Products

We identify a market gap, build a validated product (like PelliScope), and then seek commercial partners to scale it.

Path B: Partner-Initiated R&D

You bring a defined challenge. We build the dedicated AI solution, acting as your external deep-tech R&D team.

Our Philosophy

HawkFranklin’s long-term vision is to innovate science with commercial rigor. Our team spans physicists, chemists, biologists, and AI engineers who are building breakthroughs across quantum computing, finance, and healthcare.

"We are a resilient, self-funded team. We will succeed with or without external funding—this is an opportunity to join a team that is already moving forward."

Broader Biomedical Portfolio

OncoGemma

AI agents for digital pathology analysis

C-Risq

Multi-omics for cancer risk stratification

MedDiscover

RAG copilot for biomedical Q&A

Clinical FM

Foundation models for tabular EHR data

Beyond PelliScope, we maintain specialist pods across these domains to spin up commercialization-ready products wherever the science demands it.